Public consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines Despite successful efforts to control meningitis in several regions of the world, it continues to be a…
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the…
Lilly’s tripeptide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to…
Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc. Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Provention Bio, Inc.…
REGENERON AND ALNYLAM REPORT POSITIVE INTERIM PHASE 1 CLINICAL DATA ON ALN-APP, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ALZHEIMER’S DISEASE AND CEREBRAL AMYLOID ANGIOPATHY Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today positive interim results from the ongoing single ascending dose…
Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients Novartis today announced detailed results from the Phase III APPOINT-PNH trial of investigational oral monotherapy iptacopan…
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.-based…
Boehringer Ingelheim inaugurates the largest European development center for biotechnology Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as…
Lilly to Divest BAQSIMI to Amphastar In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company…
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA Daiichi Sankyo (TSE: 4568) today announced thatthe U.S. Food and Drug Administration (FDA) has extended the review period for the New DrugApplication (NDA) of quizartinib in…
WHO releases new guide on developing national programmes for age-friendly cities and communities As population ageing and urbanization rapidly progress worldwide, making our cities and communities more age-friendly is crucial to maximise the opportunities offered by longer lives. A new…
